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To determine the prevalence of pulmonary dysfunction in lupus erythematosus, 24 patients with systemic
lupus erythematosus (SLE) and 5 patients with discoid lupus erythematosus (DLE) were studied. Diffusing
capacity for carbon monoxide was abnormal in 17 (71 percent) SLE patients. A restrictive ventilatory defect
was present in 6 (25 percent) and arterial hypoxemia in 4 of 23 (17 percent). The mean ratio of forced
expiratory volume in one second to forced vital capacity (FVC) was 83 percent. To test for the presence of
small airways disease, maximum expiratory flow rate at 50 percent ofFVC was measured on air and on an 80
percent helium-20 percent oxygen mixture. Ten patients (5 smokers and 5 nonsmokers) with SLE were
nonresponders to helium suggesting small airways disease. Pulmonary dysfunction was present in 90 percent
(9/10) of SLE patients with a previous history of pleuritis and/or pneumonitis, and in 71 percent (10/14)
without respiratory symptoms or history of lung disease and with a normal chest radiograph. Pulmonary
function tests were normal in DLE patients except for an abnormal response to helium and/or mild arterial
hypoxemia in two patients, all of whom were smokers. These data indicate that there is a high prevalence of
pulmonary function abnormalities in SLE including patients without clinically evident pleuropulmonary
disease.
Pleuropulmonary manifestations of systemic lupus erythematosus (SLE) have
been described in previous clinical [1-7], radiologic [8-12], and post-mortem [13-19]
studies. However, in only a few series [20-24] have detailed pulmonary function tests
been used to assess the nature of alterations in respiratory function in SLE. A
decreased diffusing capacity for carbon monoxide is the most commonly observed
abnormality [20,21,24], and is considered the most sensitive screening test for
pulmonary abnormalities in SLE [24]. A restrictive ventilatory defect has been noted
in a few instances [20,22,23].
An investigation of pulmonary function in patients with discoid lupus erythema-
tosus (SLE) has not been reported previously and the possibility of lung dysfunction
in such patients cannot be excluded.
The primary purpose of this study was to assess pulmonary function, including
evidence of small airways disease, in patients with systemic and discoid lupus
erythematosus.
PATIENTS AND METHODS
Twenty-four patients with an established diagnosis ofSLE were evaluated. All had
multisystemic involvement and the clinical diagnosis was confirmed in all 24 by
serum factors (positive antinuclear antibody tests and positive LE preparations), and
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in 19 by skin or renal biopsies. Of the 17 patients with renal biopsies, eight had a
diffuse proliferative lesion (Nos. 5,8,9,10,12,21,22,23), three a membranous lesion
(Nos. 3,6,13) and six a focal lesion (Nos. 7,11,14,15,19,24) documented prior to
pulmonary function testing. In addition, five patients with a skin biopsy proven
diagnosis of DLE, without clinical evidence of systemic involvement, were studied.
Clinical history, respiratory symptoms, physical examination and chest radiographic
findings were determined on the day of pulmonary function testing.
Tests of pulmonary function included maximum expiratory flow rates breathing
air and then an 80 percent helium-20 percent oxygen mixture. The maximum
expiratory flow volume (MEFV) curves were measured with a pneumotachygraph
integrator system of Virgulto and Bouhuys [25] and a Brush 500 High Performance
XY recorder (Gould Inc., Cleveland, Ohio). The pneumotachygraph was calibrated
for air and helium with a flow volume calibrator [26]. The MEFV curves breathing
helium were done according to the method of Dosman et al. [27]. The MEFV curves
breathing air and helium were superimposed and maximal flow rates at 50 percent of
vital capacity on air (MEF50) and helium (MEF50He) were calculated. The mean of
the two most reproducible MEFV curves for air and helium was used. The flow rate
response breathing helium compared to air was expressed in percent as A He =
(MEF50He - MEF50)/MEF50 x 100. Patients with A He less than 20 percent were
considered nonresponders to breathing helium suggesting small airways disease
[27,28].
Lung volumes were determined by the nitrogen washout method. Diffusing
capacity for carbon monoxide (DLCO) was measured by the single breath method of
Ogilvie et al. [29] and results were corrected for anemia using the equation of
Dinakara et al. [30]. Arterial blood gas determinations were done in the sitting
position breathing ambient air.
All patients had posterior-anterior and lateral chest radiographs on the day of
pulmonary function testing. Renal function (blood urea nitrogen and serum creati-
nine) also was determined in all patients on the day of the study.
RESULTS
Patients with SLE were classified as follows:
Group 1: Patients with respiratory symptoms; history of pleuropulmonary
disease and/or an abnormal chest radiograph (10 patients).
Group 2: Patients without respiratory symptoms, history of pleuropulmonary
disease or chest radiographic abnormalities (14 patients).
Table 1 summarizes the clinical features of Group 1 patients. Two of these Group 1
patients (Nos. 2 and 4) and five Group 2 patients (Nos. 11,14,17,18, and 21) were
smokers (Table 2). All five DLE patients were smokers and none had respiratory
symptoms, a history of pleuropulmonary disease or an abnormal chest radiograph.
Table 2 shows that patients with SLE ranged in age from 15 to 59 years and with
DLE from 33 to 60 years. One Group 1 patient was a male; all other patients with
SLE and DLE were females. In none of the 24 SLE patients was the blood urea
nitrogen greater than 20 mg/ 100 ml or serum creatinine greater than 1.5 mg/ 100 ml
when pulmonary function was determined. All but three patients with SLE (Nos.
2,7,20) were receiving corticosteroids at the time of the study. Nine patients (Nos.
5,6,9,10,12,13,14,17,23) were receiving azathioprine in addition to corticosteroids.
All DLE patients were receiving only topical corticosteroid therapy.
Table 2 shows pulmonary function results for SLE and DLE patients. Measure-
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ment of diffusing capacity was abnormal, less than 70 percent ofpredicted [31], in 17
of 24 patients with SLE. In these 17 mean DLCO was 55 percent ofpredicted (range
36-69 percent). Nine of 10 patients (90 percent) in Group 1 had an abnormal DLCO.
An abnormal DLCO was also present in 8 of 14 (57 percent) Group 2 patients who
had no clinical or chest radiographic manifestations of lung involvement.
Forced vital capacity and lung volumes suggested a restrictive pattern of ventila-
tion in 6 of the 24 SLE patients (Nos. 2,3,5,9,19 and 23), and each ofthese 6 also had
a low diffusing capacity. Four of the 6 patients had an FVC less than 80 percent of
predicted [32] and four had a total lung capacity (TLC) less than 80 percent of
predicted [33].
The ratio of FEV, to FVC was 70 percent or greater in all 24 patients, mean 83
percent. Ten patients (5 smokers and 5 nonsmokers) were nonresponders to breath-
ing helium, ( A He < 20 percent) suggesting peripheral airway obstruction. Five
nonresponders to helium were from Group 1 and five from Group 2. Four of the 10
patients with a A helium less than 20 percent also had flow rates breathing air at 50
percent of vital capacity (V max50) that were abnormal, less than 80 percent of
predicted [32]. The other six nonresponders to helium had a normal V max50.
Arterial oxygen tension (PaO2) was mildly abnormal [34] in 4 of 23 patients (Nos.
5,9,11 and 12). The mean PaO2 of these four patients was 83 mmHg (range 80-86
mmHg). Two patients with hypoxemia were from Group 1 and two from Group 2.
The values for arterial carbon dioxide tension (PaCO2) were below 36 mmHg in 18
of 23 patients.
Among the 10 Group 1 patients a reduced diffusing capacity was the most common
pulmonary function abnormality (9), followed by a lack of response to breathing
helium (A He < 20 percent) (5), a restrictive ventilatory defect (4) and arterial
hypoxemia (2). For the 14 Group 2 patients without any other evidence ofpleuropul-
monary disease a decreased DLCO was present in 8, an abnormal response to
breathing helium in 5, arterial hypoxemia in 2 and a restrictive pattern ofventilation
in 2.
TABLE I
Clinical Features of Ten Patients with SLE and Clinically Evident Pleuropulmonary Disease
History of Pleuro- Respiratory Symptoms Chest Radiograph at Previous Chest Radio-
Pt. No. Pulmonary Disease at Time of Testing Time of Study graphic Abnormalities
I Pleuritis None Normal Obliteration of costo-
phrenic angle
2 Pleuritis Mild Dyspnea Normal Pleural Effusion
3 Chronic Interstitial Mild Dyspnea Diffuse Interstitial Diffuse Interstitial
Pneumonitis lung infiltrate lung infiltrate
4 Acute Lupus Pneumonitis Mild Dyspnea Normal Lung Infiltrate and
with Pleuritis Pleural Effusion
5 Pleuritis Mild Dyspnea Normal Pleural Effusion
6 Pleuritis Mild Dyspnea Tenting of both Tenting of both hemi-
hemidiaphragms diaphragms
7 Pleuritis None Normal Obliteration of costo-
phrenic angle
8 Acute Lupus Pneumonitis None Normal Lung Infiltrate and
Pleural Effusion
9 Aspiration Pneumonia Mild-Moderate Normal Lobar Consolidation
Dyspnea
10 Pleuritis None Normal Pleural Effusion
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Flow rates, lung volumes and DLCO were normal in all five DLE patients (Table
2). The only abnormalities detected in these patients were an abnormal V max50 A He
and in patient No. 29 and mild arterial hypoxemia in two patients (Nos. 25 and 29).
Both of these patients were smokers.
DISCUSSION
The results of this study indicate that pulmonary dysfunction in systemic lupus
erythematosus is common. Pulmonary function abnormalities (decreased DLCO,A
He < 20 percent, arterial hypoxemia, and/or a restrictive defect) were detected in 90
percent of patients (9/10) with a history of pleuritis and/or pneumonitis (Group 1)
and in 71 percent of patients (10/14) without clinically evident lung disease (Group
2). Some lung function abnormalities were noted in our group of patients with
discoid lupus. However, all DLE patients were smokers which could account for
these findings [27].
Our findings in SLE patients confirm the results of previous studies. All of the
patients in Gold and Jennings' series [20] of 20 SLE patients had abnormal
pulmonary function. All 20 had chest radiographic abnormalities and 18 had mild to
severe dyspnea. Sixteen of 17 patients tested had a decreased DLCO, and 12 oftheir
20 patients appeared to have restrictive lung disease. The authors conclude that the
single breath DLCO is the most sensitive indicator of the presence of lung involve-
ment in systemic lupus. Huang et al. [21] also noted a high prevalence of pulmonary
dysfunction in SLE patients and suggested that respiratory function may be abnor-
mal even in the absence of clinical symptoms or abnormal chest radiographs. In their
series, the DLCO was low in 4 of 6 asymptomatic SLE patients with normal chest
radiographs.
In 2 of 20 patients with SLE, Gold and Jennings [20] noted airway obstruction
indicated by a decreased FEVI /FVC percent and increased total airway resistance.
These authors did not discuss smoking history. In Hunt et al.'s series of 17 SLE
patients [22], 11 had decreased maximum mid-expiratory flow rates indicative of an
obstructive ventilatory defect. Six patients were smokers and one was an ex-smoker.
Ten of the patients with SLE in our series, of whom 5 were nonsmokers, did not
respond to helium suggesting small airways disease [28]. Maximum mid-expiratory
flow rates were normal, while breathing air, in 6 of our 10 patients who were
nonresponders to helium. Dosman et al. [27] have described normal maximum mid-
expiratory flow rates breathing ambient air in patients who did not respond to
breathing helium indicating that the latter test may be a more sensitive indicator of
peripheral airways obstruction.
The physiological abnormalities detected in this study and by others can be related
to pathological changes frequently noted inthelungs ofpatients with SLE. Purnellet
al. [19] detected interstitial pneumonitis in 29 of 54 autopsy cases of systemic lupus.
Gross et al. [17] reviewed pulmonary alterations in histologic speciments from 44
patients with SLE and found interstitial pneumonitis in 41. In addition, several
pulmonary vascular abnormalities have been observed in SLE. These include
fibrinoid necrosis [18], vasculitis [15], and thickened arterioles and arteries [15]. The
presence of interstitial pneumonitis with or without pulmonary vascular changes can
account for the restrictive defect and decreased diffusing capacity observed in our
patients and in other series [20-24].
Gross et al. [17] noted distal airway alterations in all of their autopsy cases
includingfocal panacinar emphysema. These changes could explain the small airways
obstruction detected in the present investigation. Furthermore, from the anatomic
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studies of Baggenstoss [13] it is known that basophilic mucinous edema is often
found within the peribronchial connective tissue and within the bronchus itself in
SLE. This mucinous edema could result in airway obstruction.
Lee and co-workers [35] have identified a high prevalence of impaired diffusing
capacity and restrictive ventilatory abnormalities among patients in renal failure of
various etiologies. Although it is possible that renal disease contributed to pulmonary
dysfunction in our patients, it is unlikely since none had evidence of renal insuffi-
ciency at the time of evaluation. In a recent study, Gibson et al. [24] found no higher
incidence of renal dysfunction among 30 patients with SLE and pulmonary function
abnormalities than in those without lung involvement.
Cytotoxic drugs, particularly bleomycin, methotrexate and busulfan, have been
associated with pulmonary toxicity and abnormal pulmonary function tests [36].
Nine patients in this series were receiving a cytotoxic drug (azathioprine); however,
this agent has not been established as toxic to the lungs [36]. All but three patients
with SLE were receiving corticosteroids which have been used successfully to treat
lupus pneumonitis [7]. Therefore, corticosteroids may have minimized the pulmo-
nary defects noted in the present series.
Our findings of a high prevalence of occult pulmonary dysfunction in SLE suggest
that all patients with this disease should undergo pulmonary function tests as part of
a complete assessment of organ involvement. Chest radiographs and even respiratory
questionnaires are insensitive means of detecting the presence oflung disease in SLE.
Prospective, longitudinal studies are required to determine how frequently isolated
pulmonary function abnormalities progress to clinically significant lung disease.
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